



## Current Role of Ablation in Liver Cancer Therapy

Guest Editors:

**Prof. Dr. Alessandro Vitale**

Hepatobiliary and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, 35128 Padua, Italy

**Prof. Dr. Umberto Cillo**

Hepato-Biliary-Pancreatic and Liver Transplant Unit “Chirurgia Generale 2”, Padua University Hospital, 35128 Padua, Italy

Deadline for manuscript submissions:


**closed (29 February 2024)**

### Message from the Guest Editors

Ablation therapy is a well-recognized option among hepatocellular carcinoma (HCC) treatments. Moreover, there is increasing evidence that ablation therapy could represent a potentially curative option also for other types of liver cancers (i.e., cholangiocarcinoma, colorectal or breast cancer liver metastases). Despite the improvements reached through the years, though, some innovations are still expected and desirable.

This Special Issue aims to explore the field of ablation in liver cancer therapy, examining innovative aspects and further developing poorly defined or already faced ones. A first scope is to collect additional evidence on the potential role of liver ablation for non-HCC liver cancers, such as cholangiocarcinoma, colorectal or breast cancer liver metastases. Furthermore, different ablation technologies, for example microwave rather than radiofrequency, are available and worth being compared. Other technical aspects like percutaneous or laparoscopic approach could also be addressed for useful comparisons. Innovative combination techniques with trans-arterial chemoembolization or immunotherapy are also recently being developed and studied.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)